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Abstract
Background: Tumor necrosis factor-α (TNF-α) is a proinflammatory cytokine and elevated in the regions of tissue
injury and inflammatory diseases. The deleterious effects of TNF-α on fibroblasts may aggravate heart inflammation
mediated through the up-regulation of adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1).
However, the mechanisms underlying TNF-α-induced VCAM-1 expression in cardiac fibroblasts remain unknown.
This study aimed to investigate the roles of TNF-α in VCAM-1 expression and its effects on human cardiac fibroblasts
(HCFs).
Results: The primary culture HCFs were used in this study. The results obtained with Western blotting, real
time-quantitative PCR, and promoter activity analyses showed that TNF-α-induced VCAM-1 expression was
mediated through TNF receptor (TNFR) 1-dependent gene up-regulation. Activation of TNFR1 by TNF-α
transactivated c-Src-dependent EGF receptor (EGFR) linking to PI3K/Akt cascade, and then led to transcriptional
activity of NF-κB. Moreover, the results of promoter reporter assay demonstrated that the phosphorylated p65
NF-κB turned on VCAM-1 gene expression. Subsequently, up-regulation of VCAM-1 promoted monocytes
adhesion to HCFs challenged with TNF-α determined by cell adhesion assay.
Conclusions: Taken together, these results indicate that in HCFs, activation of NF-κB by c-Src-mediated transactivation
of EGFR/PI3K/Akt cascade is required for TNF-α-induced VCAM-1 expression. Finally, increased VCAM-1 enhances
monocytes adhering to HCFs challenged with TNF-α. Understanding the mechanisms of VCAM-1 up-regulated by
TNF-α on HCFs may provide rationally therapeutic interventions for heart injury or inflammatory diseases.
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Background
Heart failure, the first cause of death in the world, is
generally defined as the inability of heart supplying
sufficient blood volume and is a progressive and
complex pathological condition [1]. The most common
initiation leading to heart failure is coronary artery
disease with myocardial infarction and hypertension
[2, 3]. The previous study indicates that pathological
fibrosis has emerged as a key target for pharmaco-
logical intervention in heart failure [4]. Several pro-
inflammatory cytokines such as tumor necrosis factor-α
(TNF-α) are elevated in acute myocardial injury and
infarction. Chronically elevated these cytokines also have
been shown to cause phenotypic and functional changes
in the constituent cell types of the heart [5–8], including
cell proliferation, production of the collagen extracellular
matrix (ECM), generation of mediator substances by the
cardiac fibroblast [9–11], and associate with heart failure
[12].
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TNF-α is a major cytokine in the pathogenesis of
cardiac injury, promoting inflammation, apoptosis, and
production of ECM [13, 14] and exerts as a potent
stimulus in inflammatory responses through up-
regulation of many genes, including cytokines, chemo-
kines, proteases, cyclooxygenase, and adhesion molecules
[15, 16]. Furthermore, inhibition of TNF-α-mediated
pathways can reduce myocardial ischemia-reperfusion
injury [13]. These results suggest that TNF-α may act as
a key mediator to elicit various heart diseases. TNF-α-
activated NF-κB is critical for the inflammatory processes
[17, 18]. In addition, TNF-α induces the expression of
inflammatory genes by activation of TNF receptor
(TNFR)-mediated diverse signaling molecules, including
c-Src family [19, 20]. As already shown in human cardiac
fibroblasts MMP-9 expression is induced by TNF-α [16].
Furthermore, our previous data showed that TNF-α can
induce MMP-9 expression through a c-Src/EFGR [6].
The c-Src family, a non-receptor tyrosine kinase, has
been shown to exert as a target of G protein-coupled
receptors (GPCRs) in transactivation of growth factor
receptors such as epidermal growth factor receptor
(EGFR) [21] and also involves in cytokine-stimulated
transactivation of growth factor receptors like EGFR in
several cell types [22].
In the serum of patients with non-ischemic heart failure,
the levels of intercellular adhesion molecule (ICAM)-1
and vascular cell adhesion molecule (VCAM)-1 are often
elevated. And the cellular infiltration is due to up-
regulation of adhesion molecules including ICAM-1 and
VCAM-1 to control cell adhesion and migration [23–26].
These raised levels of adhesion molecules correlate with
inflammatory infiltrates in the myocardial tissue [27].
VCAM-1, which exhibits low to negligible expression in
unstimulated endothelial cells, can be profoundly up-
regulated after cytokine challenge. The induction of cell
adhesion molecules mediates the tight adhesiveness of
polymorphonuclear cells (PMNs) and thus facilitates
PMNs migration across the vascular endothelial barrier
[28, 29]. Up-regulation of VCAM-1 and TNF-α has been
shown in the cardiac vascular endothelium from the pa-
tients with chronic heart failure [27, 30]. TNF-α-activated
c-Src kinase and NF-κB can regulate VCAM-1 expression
[31–33] and the soluble ICAM-1 release from osteoblast-
like MC3T3-E1 cells [34]. VCAM-1 promoter also
contains NF-κB binding sites which are regulated by
TNF-α through c-Src-dependent pathways [19]. There-
fore, cytokine-triggered VCAM-1 up-regulation in heart
diseases may be the key response for the targeted
leukocyte transmigration into extravascular space of
inflammation [29, 35]. However, the mechanisms and
effects of TNF-α on VCAM-1 expression via the acti-
vation of c-Src and NF-κB in primary human cardiac
fibroblasts (HCFs) remain unclear.
In this study, we found that TNF-α induces c-Src-
mediated signal activation in HCFs via TNFR1, in
turn initiates the activation of EGFR, PI3K/Akt, and
NF-κB. Activated NF-κB could accelerate VCAM-1
promoter activity to induce VCAM-1 expression in
HCFs. Moreover, up-regulation of VCAM-1 pro-
moted adhesion of monocytes to HCFs challenged
with TNF-α. These results provide new insights into
the TNF-α action, to up-regulate the VCAM-1 expres-




DMEM/F-12 medium, fetal bovine serum (FBS), TRIZOL,
Lipofectamine-PLUS reagent and 2′,7′-bis-(2-carbox-
yethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl ester
(BCECF/AM, B-1170) were from Invitrogen (Carlsbad,
CA). The siRNAs for TNFR1 (NM_001065, SASI_Hs01_
00033456), c-Src (NM_005417, SASI_Hs01_00097530),
EGFR (NM_005228, SASI_Hs01_00215449), p110 (NM_
006218, SASI_Hs01_00219339), Akt (NM_001014431,
SASI_Hs01_00105954), and p65 (a subunit of NF-κB,
NM_021975, SASI_Hs01_001220265) were from Sigma
(St. Louis, MO). Hybond C membrane, enhanced
chemiluminescence (ECL) and Western blotting detec-
tion system were from GE Healthcare Biosciences
(Buckinghamshire, UK). PhosphoPlus EGFR (Thr1068)
(#2236), Akt (Ser473) (#9271), and p65 NF-κB (Ser536)
(#3031) antibody kits were from Cell Signaling (Danvers,
MA). Human polyclonal antibody VCAM-1 (sc-8304),
TNFR1 (sc-52739), phospho-c-Src (Tyr139) (sc-12928-R),
c-Src (sc-18), p110 (PI3K subunit) (sc-7189), Akt (sc-
8312), and p65 (sc-7151) antibodies were from Santa Cruz
(Santa Cruz, CA). Vimentin (MS-129-P) was from
Thermo Fisher Scientific (Fremont, CA). GAPDH was
from Biogenesis (Bournemouth, UK). Peroxidase Affini-
Pure goat anti-rabbit IgG (111-035-003) and anti-mouse
IgG (115-035-003) were from Jackson ImmunoResearch
(West Grove, PA). PP1, AG1478, LY294002, SH-5, and
Bay11-7082 were from Biomol (Plymouth Meeting, PA).
TNF-α was from R&D Systems (Minneapolis, MN).
Bicinchoninic acid (BCA) protein assay kit was from
Pierce (Rockford, IL). Actinomycin D (Act. D), cyclohexi-
mide (CHI), enzymes, and other chemicals were from
Sigma (St. Louis, MO).
Human cardiac fibroblasts (HCFs) culture and treatment
Human cardiac fibroblasts (HCFs) were isolated from
human heart obtained from ScienCell Research Lab (San
Diego, CA, Cat. No. 6300) and then characterized by im-
munofluorescent staining with an antibody specific to fi-
bronectin [36]. These cells were grown in DMEM/F-12
containing 10 % FBS, 2 mM glutamine and antibiotics
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(100 U/ml penicillin G, 100 μg/ml streptomycin, and
250 ng/ml fungizone) at 37 °C in a humidified 5 % CO2
atmosphere. When the cultures reached confluence, cells
were treated with 0.05 % trypsin/0.53 mM EDTA for
1 min at 37 °C. The cell suspension was diluted with
DMEM/F-12 containing 10 % FBS and 2 mM glutamine
to a concentration of 2 × 105 cells/ml. The cells were
plated onto 12-well culture plates and made quiescent at
confluence by incubation in serum-free DMEM/F-12 for
24 h, for growth arrest as previously described [9, 37],
and then incubated with TNF-α (0.15, 1.5, 15, or 30 ng/
ml) at 37 °C for the indicated time intervals. The XTT
{sodium 3′-[1-(phenylamino-carbonyl)-3,4-tetrazolium]-
bis(4-methoxy-6-nitro) benzene sulphonic acid hydrate}
assay was performed to analyze the cell viability as previ-
ously described [38]. When the inhibitors were used,
cells were pretreated with the inhibitor for 1 h before ex-
posure to TNF-α. Treatment of HCFs with pharmaco-
logical inhibitors or TNF-α alone had no significant
effect on cell viability determined by XTT assay (data
not shown). Experiments were performed using cells
from passages 3 to 8.
Preparation of cell extracts and Western blot analysis
Growth-arrested HCFs (incubation in serum-free DMEM/
F-12 for 24 h) were incubated with TNF-α at 37 °C for the
indicated time intervals. The cells were washed with ice-
cold PBS, scraped, and collected by centrifugation at
45,000 × g for 1 h at 4 °C to yield the whole cell extract, as
previously described [33]. Samples were denatured, sub-
jected to SDS-PAGE using a 10 % (w/v) running gel, and
transferred to nitrocellulose membrane. Membranes were
incubated overnight using a phospho-c-Src, phospho-
EGFR, phospho-Akt, phospho-p65, TNFR1, EGFR, p110,
Akt, p65, or GAPDH antibody. Membranes were washed
with TTBS four times for 5 min each, incubated with a
1:2000 dilution of anti-rabbit horseradish peroxidase anti-
body for 1 h. The immunoreactive bands were detected by
ECL reagents and captured by a UVP BioSpectrum 500
Imaging System (Upland, CA). The image densitometry
analysis was quantified by UN-SCAN-IT gel software
(Orem, UT).
Total RNA extraction and real time-quantitative PCR
(RT-qPCR) analysis
Total RNA was isolated from HCFs treated with TNF-α
for the indicated time in 10-cm culture dishes with Trizol
according to the protocol of the manufacturer. The cDNA
obtained from total RNA previously described [33]. RT
(reverse transcription) of the first-strand cDNA synthesis
was performed with 2 μg of total RNA using oligo-dT
as primers in a final volume of 20 μl (2 U/μl RNase-
OUT, Cat. 10777–019, and 10 U/μl Moloney murine
leukemia virus reverse transcriptase (Cat. 28025–013)
from Invitrogen (Carlsbad, CA). The reaction was carried
out at 37 °C for 60 min.
Real-time PCR using KAPA PROBE FAST ABI Prism®
qPCR kit (KK4705, Kapa Biosystems, Wilmington, MA)
was performed with the 7500 Real-Time PCR System
(Applied Biosystems, Foster City, CA) using primers and
probe mixes for VCAM-1 (Forward: WSO_645213_001;
Reverse: WSO_645213_002; Probe: WSO_645213_003;
Invitrogen) and endogenous GAPDH (Forward: WSO_
724786_001; Reverse: WSO_724786_002; Probe: WSO_
724786_003) served as an internal control gene (Invitrogen,
Carlsbad, CA). Relative gene expression was deter-
mined by the ΔΔCt method, where Ct meant thresh-
old cycle [39]. All experiments were performed in
triplicate.
Plasmid construction, transfection, and luciferase reporter
gene assays
For construction of the VCAM-1-Luc plasmid, human
VCAM-1 promoter, a region spanning −1716 to −119 bp
(kindly provided by Dr. W.C. Aird, Department of Mo-
lecular Medicine, Beth Israel Deaconess Medical Center,
Boston, MA, USA) was inserted between MluI and XhoI
sites of pGL3-basic vector (Promega, Madison, WI). All
plasmids were prepared by using QIAGEN plasmid
DNA preparation kit. Plasmid (or siRNA) transient
transfection of HCFs was performed according to the
protocol of Lipofectamine and PLUS reagent (Invitrogen,
Carlsbad, CA) with minor modifications. Briefly, HCFs
were plated at 3 × 105 cells/ml (1 ml per well) in 12-well
culture plates for 24 h, reaching about 80 ~ 90 % conflu-
ence. Cells were washed once with PBS and 0.4 ml of
serum-free DMEM/F-12 medium was added to each
well. The 0.8 μg plasmid DNA (or 20 pmol siRNA) and
1 μl PLUS reagent complex were prepared with serum-
and antibiotics-free DMEM/F-12 for 15 min at room
temperature. Two μl Lipofectamine™ was mixed gently
with serum- and antibiotics-free DMEM/F-12. The mix-
tures were incubated for 30 min at room temperature.
The mixtures (100 μl) were added into the wells. After
transfection for 5 h, the cells were washed once with
PBS and 0.5 ml of containing 10 % FBS was added and
incubated for an additional 19 h. VCAM-1-Luc and κB-
Luc (Clontech, Palo Alto, CA) activities in HCFs were
determined as previously described [33] using a lucifer-
ase assay system (Promega, Madison, WI) according to
the manufacturer’s instructions. Firefly luciferase activ-
ities were standardized for β-galactosidase activity.
Cell adhesion assay
HCFs were placed on 6-well culture plates with cover
slips and pretreated with the pharmacological inhibitors
for 1 h before treatment with TNF-α for 16 h at 37 °C in
a humidified 5 % CO2 atmosphere. Before the adhesion
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assay, the HCFs were washed with PBS and then incu-
bated in serum-free DMEM/F-12. THP-1 cells (human
acute monocytic leukemia cell line, obtained from
ATCC) were maintained in suspension in RPMI-1640
medium supplemented with 10 % FBS, 100 U penicillin,
and 100 U streptomycin. Before labeling, THP-1 cells
were washed and resuspended in serum-free medium.
BCECF/AM (10 μM), a membrane-permeable fluores-
cent indicator with an Ex/Em = 503/520 nm, was used to
label the THP-1 cells in serum free medium for 1 h at
37 °C. After labeling, cells were washed and resuspended
in serum free medium at least three times and kept in
the dark at room temperature and then the labeled
THP-1 cell (2 × 106 cells/ml) were added to HCFs chal-
lenged with TNF-α, and cultures were incubated in a
CO2 incubator for 1 h. Non-adherent THP-1 cells were
removed and plates were gently washed twice with PBS.
The numbers of fluorescently labeled adherent THP-1
cells were determined by counting four fields per 200×
high-power field well using a fluorescence microscope
(Zeiss, Axiovert 200 M).
Statistical analysis
All data were estimated using GraphPad Prism Program
(GraphPad, San Diego, CA). Data were expressed as the
mean ± SEM and analyzed with a one-way ANOVA
followed with Wilcoxon/Kruskal-Wallis test at p < 0.05
level of significance.
Results
TNF-α induces VCAM-1 expression and monocyte
adhesion
To evaluate the effect of TNF-α on VCAM-1 protein
and mRNA expression, HCFs were incubated with
various concentrations of TNF-α for the indicated time
intervals. As shown in Fig. 1a, TNF-α induced VCAM-1
protein expression in a time- and concentration-dependent
manner, with a significant increase within 4 h, a max-
imal response within 16 h, and sustained over 24 h.
There was no change in the levels of house-keeping
protein GAPDH served as an internal control. We also
found that 30 ng/ml TNF-α induced a maximal VCAM-1
induction within 16–24 h. The concentration of TNF-α
(15 ng/ml) was used to induce sub-maximal VCAM-1
expression for the following experiments. To further
examine the effect of TNF-α on VCAM-1 mRNA ex-
pression, the levels of VCAM-1 mRNA were deter-
mined by real time-qPCR. As shown in Fig. 1b, TNF-α
(15 ng/ml) time-dependently induced VCAM-1 mRNA
accumulation in HCFs. A maximal response was ob-
tained within 4 h and sustained over 6 h during the
period of observation. Moreover, TNF-α (15 ng/ml)
also stimulated a significant increase in VCAM-1-
promoter activity within 2 h and reached a maximum
within 4 h (Fig. 1c), suggesting that TNF-α up-
regulated VCAM-1 gene expression in HCFs. We further
tested the functional activity of expressed VCAM-1 by
TNF-α in HCFs, a THP-1 monocyte adhesion assay was
performed. As shown in Fig. 1d, TNF-α induced a
significant increase of THP-1 monocyte adhesion to
TNF-α-challenged HCFs (approximate 4 folds) which
was attenuated by pretreatment with VCAM-1 neutraliz-
ing antibody (VCAM-1 nAb, 2 μg/ml). These results sug-
gested that induction of VCAM-1 enhances THP-1
monocyte adhesion to the TNF-α-challenged HCFs.
TNF-α induces de novo VCAM-1 protein synthesis via TNF
receptor-mediated manner
To determine whether the effect of TNF-α on VCAM-1
expression is dependent on de novo protein synthesis, a
transcription inhibitor Act. D and a translation inhibitor
CHI were used. As shown in Figs. 2a and b, pretreatment
with either Act. D or CHI concentration-dependently at-
tenuated TNF-α-induced VCAM-1 expression in HCFs,
suggesting that VCAM-1 expression induced by TNF-α is
mediated through the transcription and translation. To
determine whether TNF-α-induced VCAM-1 expression
is mediated through TNF receptor (TNFR), as shown in
Fig. 2c, pretreatment with TNFR neutralizing antibody
(TNFR nAb) attenuated TNF-α-induced VCAM-1 expres-
sion. Moreover, as shown in Fig. 2d, pretreatment with
Act. D (10 μM) or TNFR nAb (3 μg/ml) significantly
attenuated TNF-α-induced VCAM-1 mRNA expres-
sion (open bar) and VCAM-1 promoter activity (gray
bar). To confirm the role of TNFR1 in TNF-α-induced
VCAM-1 expression, the data showed that transfection
with TNFR1 siRNA knocked down TNFR1 protein and
attenuated the TNF-α-induced VCAM-1 expression
(Fig. 2e), suggesting that TNF-α-induced VCAM-1 ex-
pression is mediated through TNFR1-dependent man-
ner in HCFs.
Involvement of c-Src in TNF-α-induced VCAM-1
expression
TNF-α has been shown to induce expression of adhesion
molecules such as VCAM-1 in various cell types [33]. In
addition, c-Src is a critical tyrosine kinase to regulate
VCAM-1 expression in myoglobin-induced tubular in-
jury [31]. Thus, we investigated whether c-Src involved
in TNF-α-induced VCAM-1 expression in HCFs. As
shown in Figs. 3a and b, pretreatment with the inhibitor
of c-Src (PP1) attenuated TNF-α-induced VCAM-1 pro-
tein, mRNA, and promoter activity. To further observe
whether TNF-α could stimulate c-Src activation linked
to VCAM-1 expression, as shown in Fig. 3c, TNF-α
stimulated c-Src phosphorylation in a time-dependent
manner in these cells. We further confirmed the effect
of c-Src on TNF-α-induced responses, a c-Src siRNA
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was used. The data showed that transfection with c-Src
siRNA markedly knocked down c-Src protein level
and attenuated TNF-α-induced c-Src phosphorylation
(Fig. 3c) and VCAM-1 expression (Fig. 3d). Moreover,
we determined the role of TNFR in these responses, as
shown in Fig. 3e, pretreatment with TNFR nAb atten-
uated TNF-α-stimulated c-Src phosphorylation during
the period of observation, suggesting that TNF-α stim-
ulated c-Src phosphorylation via a TNFR-dependent
manner. These results suggested that TNF-α-induced
Fig. 1 TNF-α induces VCAM-1 expression in HCFs. a Time and concentration dependence of TNF-α-induced VCAM-1 expression, HCFs were
treated with various concentrations of TNF-α (0.15, 1.5, 15, or 30 ng/ml) for the indicated time intervals. The cell lysates were prepared and blotted
using VCAM-1 or GAPDH (as a control) antibody. b For VCAM-1 mRNA expression, cells were treated with TNF-α (15 ng/ml) for the indicated
times. The VCAM-1 mRNA expression was analyzed by real time-qPCR. c For VCAM-1 promoter activity, cells were transiently transfected with a
VCAM-1-Luc reporter gene and then treated with TNF-α (15 ng/ml) for the indicated time intervals. The promoter luciferase activity was analyzed
and normalized to β-galactosidase activity as described in “Methods”. d For adhesion activity, cells were treated with TNF-α for 16 h and washed
with PBS prior to the addition of THP-1 monocytes. Moreover, functional expression of VCAM-1 was determined by THP-1 monocyte adhesion
assay in the absence or presence of VCAM-1 neutralizing antibody (VCAM-1 nAb, 2 μg/ml). Data are expressed as mean ± SEM of three individual
experiments (n = 3). *P < 0.05, #P < 0.01 vs. vehicle (A-C) or TNF-α (d) alone
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Fig. 2 TNF-α induces de novo VCAM-1 protein synthesis via TNFR1-mediated manner. a, b Cells were pretreated with various concentrations of
actinomycin D (Act. D, transcription inhibitor) or cycloheximide (CHI, translation inhibitor) and then incubated with 15 ng/ml TNF-α for 16 h. The
cell lysates were analyzed by Western blot using a VCAM-1 or GAPDH (as a control) antibody. c Involvement of TNFR in TNF-α-induced VCAM-1
expression, cells were pretreated with various concentrations of TNFR neutralizing antibody (TNFR nAb; 1, 3, or 10 μg/ml) for 1 h and then
incubated with TNF-α for 16 h. d Cells were pretreated with Act. D (10 μM) or TNFR nAb (3 μg/ml) for 1 h and then incubated with TNF-α for
4 h. The VCAM-1 mRNA (open bar) and promoter activity (gray bar) were analyzed by real time-qPCR and promoter assay, respectively. e Cells
were transfected with siRNA of TNFR1 or scramble (scrb, as a control) for 24 h and then incubated with TNF-α for 16 h. The VCAM-1 protein
(a, b, c, e) was analyzed by Western blot using respective antibodies. Data are expressed as mean ± SEM of three individual experiments (n = 3).
*P < 0.05, #P < 0.01 vs. TNF-α alone
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VCAM-1 expression is mediated through a c-Src-mediated
pathway in HCFs.
c-Src-dependent transactivation of EGFR is involved in
TNF-α-induced VCAM-1 expression
Several growth factor receptors such as EGFR activation
have been shown to be regulated by c-Src leading to induc-
tion of various genes [40]. Thus, we investigated the role of
EGFR in TNF-α-induced VCAM-1 expression in HCFs. As
shown in Figs. 4a and b, pretreatment with an EGFR inhibi-
tor AG1478 concentration-dependently inhibited TNF-α-
induced VCAM-1 protein, mRNA, and promoter activity.
To determine whether TNF-α could stimulate phosphoryl-
ation of EGFR linked to VCAM-1 expression, as shown in
Fig. 4c, TNF-α time-dependently stimulated EGFR phos-
phorylation which was attenuated by pretreatment with
AG1478 (10 μM) during the period of observation. We fur-
ther confirmed the role of EGFR in TNF-α-induced
VCAM-1 expression, the results showed that transfection
with EGFR siRNA knocked down EGFR protein level and
attenuated TNF-α-induced VCAM-1 expression (Fig. 4d).
We also investigated the role of TNFR-mediated c-Src cas-
cade in TNF-α-stimulated EGFR phosphorylation. As
shown in Fig. 4e, pretreatment with TNFR nAb or PP1
attenuated TNF-α-stimulated EGFR phosphorylation dur-
ing the period of observation. These results suggested that
c-Src-dependent EGFR transactivation contributes to TNF-
α-induced VCAM-1 expression in HCFs.
TNF-α induces VCAM-1 expression via PI3K/Akt cascade
The PI3K/Akt signaling cascade, the direct downstream
molecules of EGFR, plays a key role in various physio-
logical and pathological processes. Previous studies have
indicated that PI3K/Akt pathway is involved in VCAM-1
induction by TNF-α in various cell types [40, 41]. In this
study, we investigated the effects of PI3K (LY294002) and
Akt (SH-5) inhibitors on TNF-α-induced VCAM-1 ex-
pression. As shown in Figs. 5a and b, pretreatment with
LY294002 or SH-5 markedly attenuated TNF-α-induced
VCAM-1 protein, mRNA, and promoter activity. To de-
termine whether TNF-α stimulates activation of Akt, the
data showed that TNF-α time-dependently stimulated Akt
phosphorylation which was inhibited by pretreatment with
LY294002 (10 μM) during the period of observation
(Fig. 5c). To confirm the roles of PI3K/Akt in TNF-α-
induced VCAM-1 expression in HCFs, as shown in Fig. 5d,
transfection with siRNA for p110 (a PI3K subunit) or Akt
knocked down p110 or Akt protein, respectively, and
Fig. 3 Involvement of c-Src in TNF-α-induced VCAM-1 expression. a, b Cells were pretreated with (a) various concentrations of PP1 (c-Src inhibitor;
0.1, 0.3, or 1 μM) (B) 1 μM PP1 for 1 h and then incubated with TNF-α for 16 h (a) or 4 h (b, c) Time dependence of TNF-α-induced c-Src
phosphorylation, cells were treated with TNF-α (15 ng/ml) for the indicated time intervals in the presence or absence of c-Src siRNA. d Cells were
transfected with siRNA of c-Src or scramble (scrb, as a control) for 24 h and then incubated with TNF-α for 16 h. e Cells were treated with TNF-α
for the indicated time intervals in the presence or absence of TNFR nAb (10 μg/ml). The VCAM-1 protein (a, d), and mRNA and promoter activity
(b) were analyzed by Western blotting, real time-qPCR, and promoter assay, respectively. The c-Src phosphorylation (c, e) was analyzed by
Western blot. Data are expressed as mean ± SEM of three individual experiments (n = 3). *P < 0.05, #P < 0.01 vs. TNF-α alone
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significantly attenuated TNF-α-induced VCAM-1 expres-
sion. We further determined the role of c-Src-dependent
EGFR signaling pathway in TNF-α-stimulated Akt phos-
phorylation. As shown in Fig. 5e, pretreatment with TNFR
nAb, c-Src siRNA, or AG1478 markedly attenuated TNF-
α-induced Akt phosphorylation in HCFs. These results in-
dicated that TNF-α-induced VCAM-1 expression is
mediated through a c-Src-dependent transactivation of
EGFR-PI3K/Akt-dependent signaling pathway in HCFs.
NF-κB is required for TNF-α-induced VCAM-1 expression
Inflammatory responses following stimulation with cyto-
kines such as TNF-α are highly dependent on activation
of the transcription factor NF-κB. Moreover, TNF-α has
Fig. 4 TNF-α-induced VCAM-1 expression is mediated through c-Src-dependent transactivation of EGFR. a, b Cells were pretreated with various
concentrations of AG1478 (EGFR inhibitor; 0.1, 1, or 10 μM) for 1 h and then incubated with TNF-α for 16 h (a) or 4 h (b). c Time dependence of
TNF-α-induced EGFR phosphorylation, cells were treated with TNF-α (15 ng/ml) for the indicated time intervals in the presence or absence of
AG1478 (10 μM). d Cells were transfected with siRNA of EGFR or scramble (scrb, as a control) for 24 h and then incubated with TNF-α for 16 h.
e Cells were treated with TNF-α for the indicated time intervals in the presence or absence of TNFR nAb (3 μg/ml) or PP1 (1 μM). The VCAM-1
protein (a, d), and mRNA and promoter activity (b) were analyzed by Western blotting, real time-PCR, and promoter assay, respectively. The EGFR
phosphorylation (c, e) was analyzed by Western blot. Data are expressed as mean ± SEM of three individual experiments (n = 3). *P < 0.05,
#P < 0.01 vs. TNF-α alone
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been shown to induce expression of various genes such as
VCAM-1 through NF-κB in several cell types [33]. Thus,
the involvement of NF-κB in VCAM-1 induction by TNF-
α in HCFs was confirmed by using an NF-κB pharmaco-
logical inhibitor Bay11-7082. As shown in Fig. 6a,
pretreatment with Bay11-7082 caused a concentration-
dependent attenuation of VCAM-1 expression induced by
TNF-α in HCFs. We further investigated the effects of
Bay11-7082 on TNF-α-induced VCAM-1 mRNA and pro-
moter activity. As shown in Fig. 6b, pretreatment with
Bay11-7082 (3 μM) attenuated TNF-α-induced VCAM-1
mRNA and promoter activity. To determine whether
TNF-α stimulates activation of NF-κB, the data showed
that TNF-α time-dependently stimulated p65 (a subunit
of NF-κB) phosphorylation which was attenuated by
pretreatment with Bay11-7082 during the period of
Fig. 5 TNF-α induces VCAM-1 expression via PI3K/Akt cascade. a, b Cells were pretreated with various concentrations of LY294002 (PI3K inhibitor;
0.1, 1, or 10 μM) or SH-5 (Akt inhibitor; 0.01, 0.1, or 1 μM) for 1 h and then incubated with TNF-α for 16 h (a) or 4 h (b). c Time dependence of
TNF-α-induced Akt phosphorylation, cells were treated with TNF-α (15 ng/ml) for the indicated time intervals in the presence or absence of
LY294002 (10 μM). d Cells were transfected with siRNA of p110 (a PI3K subunit), Akt, or scramble (scrb, as a control) for 24 h and then incubated
with TNF-α for 16 h. e Cells were treated with TNF-α for the indicated time intervals in the presence or absence of TNFR nAb (10 μg/ml), c-Src
siRNA, or AG1478 (10 μM). The VCAM-1 protein (a, d), and mRNA and promoter activity (b) were analyzed by Western blotting, real time-PCR, and
promoter assay, respectively. The Akt phosphorylation (c, e) was analyzed by Western blot. Data are expressed as mean ± SEM of three individual
experiments (n = 3). *P < 0.05, #P < 0.01 vs. TNF-α alone
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Fig. 6 (See legend on next page.)
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observation (Fig. 6c). Furthermore, to confirm the role
of NF-κB in TNF-α-induced VCAM-1 expression, as
shown in Fig. 6d, transfection with p65 siRNA knocked
down p65 protein level and attenuated TNF-α-induced
VCAM-1 expression, suggesting that NF-κB is essential
for these responses. We further determined whether
involvement of c-Src-dependent EGFR/PI3K/Akt signal-
ing pathway in TNF-α-stimulated p65 phosphorylation
in HCFs. As shown in Fig. 6e, pretreatment with TNFR
nAb, c-Src siRNA, AG1478, LY294002, or Akt siRNA
markedly attenuated TNF-α-stimulated p65 phosphor-
ylation, suggesting that TNFR/c-Src/EGFR/PI3K/Akt
cascade is involved in TNF-α-stimulated p65 phosphoryl-
ation in HCFs. Moreover, to determine whether TNF-α en-
hances the transcriptional activity of NF-κB, as shown in
Fig. 6f, we observed that TNF-α enhanced NF-κB tran-
scriptional activity in a time-dependent manner and a
maximal response was achieved within 6 h (upper panel),
which was markedly inhibited by pretreatment with TNFR
nAb, PP1, AG1478, LY294002, or Bay11-7082 (lower
panel). Taken together, these data demonstrated that TNF-
α induces NF-κB-dependent VCAM-1 expression via a
TNFR/c-Src/EGFR/PI3K/Akt signaling pathway in HCFs.
TNF-α promotes monocyte adhesion to HCFs through a
c-Src-dependent EGFR/PI3K/Akt/NF-κB pathway
Our previous data (Fig. 1d) have shown that TNF-α in-
duces VCAM-1 expression and then enhancing monocyte
adhesion to HCFs. Subsequently, we further investigated
whether these signaling molecules investigated above are
involved in enhancing monocyte adhesion to HCFs chal-
lenged with TNF-α and their respective pharmacological
inhibitors were used. As shown in Fig. 7a, pretreatment
with Act. D (10 μM), CHI (1 μM), TNFR nAb (3 μg/ml),
PP1 (1 μM), AG1478 (10 μM), LY294002 (10 μM), SH-5
(1 μM), or Bay11-7082 (3 μM) markedly blocked the
adhering of THP-1 to TNF-α-challenged HCFs. These
results indicated that TNF-α-induced VCAM-1 ex-
pression is mediated through a c-Src-dependent EGFR/
PI3K/Akt/NF-κB pathway which also contributes to
enhancement of monocyte adhering to these TNF-α-
induced HCFs.
Discussion
Up-regulation of adhesion molecules on the surface of
the heart cells may play a key role in recruitment and in-
filtration of leukocytes at sites of inflammation in heart
inflammatory disorders [8, 23, 24, 26]. Cardiac fibro-
blasts play critical role in the development of cardiac fi-
brosis [4, 10, 11, 42]. Previous reports indicate that
TNF-α-treatment can induce VCAM-1 expression in rat
primary cardiac fibroblasts [43] and mediate the mono-
cyte adhesion [44, 45]. We found that VCAM-1 nAb can
reduce the monocyte adhesion (about 37 %) on HCFs
challenged with TNF-α (Fig. 1d). However, TNFR nAb
treatment can reduce the monocyte adhesion on HCFs
about 73 % (Fig. 7a). We suggest that TNF-α induces
not only VCAM-1 but also other adhesion molecules on
HCFs which contribute to monocyte adhesion.
Previous study indicates that serum TNF-α concentra-
tions of chronic heart failure patients (4.5 ± 0.5 pg/ml) are
higher than normal (2.6 ± 0.4 pg/ml) [46]. However, treat-
ments with these concentrations could not induce a sig-
nificant gene expression in our system (data not shown).
To obtain the optimal VCAM-1 expression, the higher
concentrations of TNF-α were used to challenge HCFs.
TNF-α has been confirmed to induce the expression of
VCAM-1 in synovial fibroblasts [33]. Moreover, TNF-α
has also been shown to activate various signals including
MAPKs in several cell types [6, 33], but the intracellular
signaling mechanisms leading to VCAM-1 expression re-
main unclear in HCFs. Transactivation of the receptor
tyrosine kinases (RTKs), EGFR especially, has been shown
to occur in response to several cytokines such as TNF-α
[47], which might contribute to various cellular functions
[35]. Although transactivation of EGFR by GPCR agonists
has been well studied [35, 48], the signaling mechanisms
by which TNF-α-stimulated transactivation of EGFR in
HCFs remain unclear.
In this study, up-regulation of VCAM-1 by TNF-α
is mediated through transactivation of c-Src/EGFR
which were attenuated by their respective inhibitors
(PP1 and AG1478) and siRNAs transfection, suggest-
ing the involvement of c-Src/EGFR in these responses
(Figs. 3 and 4). In addition, we found that EGFR was
(See figure on previous page.)
Fig. 6 The NF-κB is required for TNF-α-induced VCAM-1 expression. a, b Cells were pretreated with various concentrations of Bay11-7082
(NF-κB inhibitor; 0.1, 1, or 3 μM) for 1 h and then incubated with TNF-α for 16 h (a) or 4 h (b). c Time dependence of TNF-α-induced
p65 NF-κB phosphorylation, cells were treated with TNF-α (15 ng/ml) for the indicated time intervals in the presence or absence of
Bay11-7082 (3 μM). d Cells were transfected with siRNA of p65 or scramble (scrb, as a control) for 24 h and then incubated with TNF-α
for 16 h. e Cells were treated with TNF-α for the indicated time intervals in the presence or absence of TNFR nAb (10 μg/ml), c-Src
siRNA, or AG1478 (10 μM), LY294002 (10 μM), or Akt siRNA. f Time dependence of TNF-α-stimulated NF-κB transcription activity, cells were
transfected with a NFκB-luciferase reporter gene and then exposed to TNFα for the indicated time intervals (upper panel). Moreover, the
transfected cells were pretreated with the inhibitor of NF-κB (Bay11-7082), TNFR nAb, c-Src (PP1), EGFR (AG1478), or PI3K (LY294002) for
1 h and then incubated with TNF-α for 6 h (lower panel). The VCAM-1 protein (a, d), mRNA (b), and promoter activity (b, f) were analyzed by Western
blotting, real time-qPCR, and promoter assay, respectively. The Akt phosphorylation (c, e) was analyzed by Western blot. Data are expressed as
mean ± SEM of three individual experiments (n = 3). *P < 0.05, #P < 0.01 vs. TNF-α alone
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a downstream component of c-Src, since TNF-α-
induced EGFR phosphorylation was attenuated by PP1
(Fig. 4e), whereas AG1478 had no effect on c-Src
phosphorylation (data not shown), and subsequent
up-regulation of VCAM-1 and adhesion of monocytes
(Fig. 7a). These results suggested that transactivation
of EGFR plays a critical role in TNF-α-induced
VCAM-1 expression and monocyte adhesion, consist-
ent with previous report showing the involvement of
EGFR transactivation in TNF-α-induced VCAM-1
expression in human tracheal smooth muscle cells
(HTSMCs) [40].
The PI3K/Akt cascade is the downstream components
of EGFR activation, which is implicated in the pathogen-
esis of inflammatory responses [49, 50] through the induc-
tion of inflammatory gene expression [40, 51]. PI3K could
initiate a series of events that lead to Akt activation [52].
Moreover, TNF-α-stimulated activation of PI3K/Akt path-
way has been reported in various cell types [6, 22]. As ex-
pected, our results also showed that both the inhibitors of
PI3K (LY294002) and Akt (SH-5) could significantly at-
tenuate the TNF-α-induced VCAM-1 expression (Fig. 5a)
and monocyte adhesion (Fig. 7a). We further confirmed
this hypothesis by the results that transfection with p110
siRNA (a PI3K subunit) or Akt siRNA also attenuated the
TNF-α-induced VCAM-1expression (Fig. 5d). Altogether,
these results suggested that VCAM-1 induction by TNF-α
is mediated through a PI3K/Akt-dependent cascade in
HCFs, consistent with previous study that PI3K/Akt
cascade may be an important pathway in regulating
VCAM-1 expression by TNF-α in various cell types
[40, 41]. Moreover, TNF-α-stimulated Akt phosphoryl-
ation was attenuated by the inhibitors of TNFR nAb,
c-Src siRNA, EGFR (AG1478) (Fig. 5e) and PI3K
(LY294002) (Fig. 5c). These results indicated that
TNF-α-induced VCAM-1 expression may be sequentially
mediated through a c-Src-dependent EGFR/PI3K/Akt
cascade in HCFs.
Inflammatory responses following exposure to cyto-
kines are highly dependent on activation of NF-κB which
plays an important role in expression of several inflam-
matory genes [17, 18, 53]. NF-κB activity is increased
and critically implicates in the development of cardiac fi-
brosis and pathologic cardiac remodeling. Moreover,
NF-κB is a key regulator in myofibroblast differentiation
[54]. Our previous study also demonstrated that c-Src-
dependent NF-κB activation is essential for the expres-
sion of VCAM-1 induced by TNF-α in HTSMCs,
synovial fibroblasts and osteoblast-like MC3T3-E1 cells
[33, 34, 47]. In the present study, the role of NF-κB in
TNF-α-induced VCAM-1 expression is confirmed by an
NF-κB inhibitor (Bay11-7082, Fig. 6a) and p65 siRNA
transfection (Fig. 6d), indicating that NF-κB involves in
TNF-α-induced VCAM-1 expression. Moreover, we
found that the increase in p65 NF-κB phosphorylation
correlates with an increase of NF-κB transcriptional
activity induced by TNF-α (Figs. 6e and f, upper panel).
TNF-α-stimulated p65 phosphorylation and transcrip-
tional activity is attenuated by PP1, AG1478, LY294002,
and Bay11-7082 or transfection with c-Src and Akt
siRNAs (Figs. 6e and f, lower panel), suggesting that TNF-
α-stimulated NF-κB activation is mediated through a c-
Src-dependent transactivation EGFR/PI3K/Akt cascade in
HCFs. These findings are consistent with several reports
Fig. 7 Up-regulated VCAM-1 by TNF-α contributes to enhancement
of monocyte adhering to HCFs. a For adhesion activity, cells were
pretreated with Act. D (transcription inhibitor, 10 μM), CHI (translation
inhibitor, 1 μM), TNFR-nAb (10 μg/ml), PP1 (c-Src, inhibitor, 1 μM),
AG1478 (EGFR inhibitor, 10 μM), LY294002 (PI3K inhibitor, 10 μM), SH-5
(Akt inhibitor, 1 μM), or Bay11-7082 (NF-κB inhibitor, 3 μM) for 1 h and
then incubated with TNF-α (15 ng/ml) for 16 h prior to the addition of
THP-1 monocytes. The adhesion activity was determined by cell
adhesion assay as described in Fig. 1. Data are expressed as
mean ± SEM of at least three individual experiments (n = 3).
#P < 0.01 vs. TNF-α alone. b Schematic presentation of the summary
of this work. In HCFs, TNF-α/TNFR1-mediated signaling pathways linked
to up-regulation of VCAM-1. TNF-α induces VCAM-1 expression via
c-Src-dependent transactivation of EGFR/PI3K/Akt cascade linking to
p65 NF-κB transcription activity. Finally, TNF-α-up-regulated VCAM-1
contributes to enhancement of monocyte adhering to HCFs
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indicating that activation of NF-κB is mediated via EGFR/
PI3K/Akt in various cell types [55, 56]. However, studies
on the role of the PI3K/Akt pathway in NF-κB-dependent
gene expression are controversial. Our previous study
shows that TNF-α-induced MMP-9 expression via NF-κB
activation is independent on the PI3K/Akt cascade in
HTSMCs [21]. The recent reports also indicate that
MMP-9 is a responsive gene of NF-κB and AP-1 [57]
and the necrotic cardiomyocytes can release heat-labile
proinflammatory signal to activate NF-κB in cardiac
fibroblasts [58].
The infiltration of immune cells is due to up-
regulation of adhesion molecules including ICAM-1
and VCAM-1 [23, 24, 26] which contribute to several
chronic inflammatory diseases including cardiovascu-
lar diseases. Moreover, the elevated levels of ICAM-1
and VCAM-1 are often found in the serum of pa-
tients with non-ischemic heart failure. These raised
serum levels of adhesion molecules correlate with in-
flammatory infiltrates in the myocardial tissue [27].
The VCAM-1, which exhibits low to negligible ex-
pression on un-stimulated endothelial cells, can be
profoundly up-regulated by cytokines. The cardiac
fibroblasts are versatile cells with the potential to
activate an array of genes that are able to initiate
and propagate inflammation in heart diseases. Up-
regulation of VCAM-1 and TNF-α has been shown
in the cardiac vascular endothelium from patients
with chronic heart failure [27, 30]. However, the ef-
fects of TNF-α-induced VCAM-1 expression between
cardiac fibroblasts and immune cells remain unclear.
In this study, we demonstrated that TNF-α enhanced
monocyte adhesion through up-regulation of VCAM-
1, as a marker of immune cell infiltration (Fig. 1d).
Moreover, these signaling components of VCAM-1 in-
duction by TNF-α were involved in TNF-α-enhanced
monocyte adhesion attenuated by their respective
pharmacological inhibitors (Fig. 7a). These results in-
dicated that TNF-α-induced VCAM-1 expression via
a c-Src-dependent transactivation of EGFR/PI3K/Akt
links to NF-κB pathway which increases the mono-
cytes adhered to TNF-α-challenged HCFs. These
results are consistent with reports indicating that
TNF-α enhanced immune cells adhesion via in-
creased VCAM-1 expression in RASFs or HTSMCs
[33, 40]. Therefore, infiltration of immune cells into
myocardium exerts bidirectional cross talk with HCFs
which can be mediated by paracrine signals, direct
cell-cell interactions, and indirect interaction via
ECM. Both cell types and their cross talk are im-
portant determinants of structural, mechanical char-
acteristics in the healthy and remodeled myocardium
[59]. Cardiac fibroblasts play many of roles in
cardiac development and remodeling. HCFs are the
predominant type of cells involved in ECM turnover
and deposition in the heart [60], which leads to ex-
cessive deposition of ECM and fibroblast accumula-
tion and results in distorted organ architecture and
function.
Conclusions
In summary, we reported here that TNF-α induced
the expression of VCAM-1 gene in HCFs. The TNFR1,
c-Src, EGFR, PI3K/Akt, and NF-κB cooperatively medi-
ated these effects of TNF-α. Based on the observations
from literatures and our findings, Fig. 7b depicts a
model for the signaling mechanisms implicated in TNF-
α-induced VCAM-1 expression in HCFs. These findings
suggest that TNF-α-induced VCAM-1 expression might
play a critical role in heart inflammatory disorders
mediated through c-Src-dependent transactivation of
EGFR, PI3K/Akt, and NF-κB signaling pathways in
HCFs. The results provide new insights into the mecha-
nisms of TNF-α action on HCFs to up-regulate the
VCAM-1 expression and then amplified the inflamma-
tory responses, supporting the hypothesis that TNF-α
may play a key role in the development of cardiac
diseases.
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